Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Regression of Liver Fibrosis by Tenofovir Alafenamide (TAF) in Treatment-Naive CHB Related Fibrosis/Cirrhosis: a 96w Open-label Multicenter Study

NCT04939441 is registered in ClinicalTrials.gov with Jidong Jia as lead sponsor.

NCT NCT04939441
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04939441 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Regression of Liver Fibrosis by Tenofovir Alafenamide (TAF) in Treatment-Naive CHB Related Fibrosis/Cirrhosis: a 96w Open-label Multicenter Study
Lead sponsor
Jidong Jia
Phase
Phase 4
Overall status
Unknown status
Start date
April 20, 2021
Completion date
May 1, 2025
Enrollment
100 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis b